MAVERIC Trial
MAVERIC Trial of the ARTO System Encompasses Four Continents and 15 centers of Excellence
The MAVERIC (MitrAl ValvE RepaIr Clinical) trial program is a prospective, single arm group of studies evaluating the safety and performance of the ARTO System in patients with congestive heart failure associated with mitral regurgitation.
"Ten years ago, I had a heart attack and was treated with a stent. When my condition worsened, I was offered this operation, which made me feel much better. These days, I exercise with my hunting dog: I cycle and he follows me. He is very strong, so have to keep up. And I do!"
– E.L., MAVERIC Trial patient, Latvia
MAVERIC Trial Design
Primary Outcome Measures
- Major Adverse Event rate* to 30 days
- Reduction of MR Grade mitral regurgitation at 30 days
- Acute Technical Succes (MVARC Definition)
* death, stroke, MI, cardiac tamponade, device-related cardiac surgery, and renal failure.
Secondary Outcome Measures
- MAE Rate & MR reduction at 6 Months, 1, 2 and 3 years
- NYHA Class
- Heart failure hospitalization
Key Inclusion Criteria
- Refused for MV surgery
- NYHA Class II-IV of any etiology
- Symptomatic with MR grade ≥ 2+
MAVERIC Trial
Immediate and Long-Term Maintained Results
45 patients enrolled in the MAVERIC Trial provide evidence that treatment with the ARTO System results in meaningful, immediate and long term MR reduction.
